AIM: To investigate the precise roles of CAR in CCl(4)-induced acute hepatotoxicity. METHODS: To prepare an acute liver injury model, CCl(4) was intraperitoneally injected in CAR+/+ and CAR-/- mice. RESULTS: Elevation of serum alanine aminotransferase and extension of centrilobular necrosis were slightly inhibited in CAR-/- mice compared to CAR+/+ mice without PB. Administration of a CAR inducer, PB, revealed that CCl(4)-induced liver toxicity was partially inhibited in CAR-/- mice compared with CAR+/+ mice. On the other hand, androstanol, an inverse agonist ligand, inhibited hepatotoxicity in CAR+/+ but not in CAR-/- mice. Thus, CAR activation caused CCl(4) hepatotoxicity while CAR inhibition resulted in partial protection against CCl(4)-induced hepatotoxicity. There were no differences in the expression of CYP2E1, the main metabolizing enzyme for CCl(4), between CAR+/+ and CAR-/- mice. However, the expression of other CCl(4)-metabolizing enzymes, such as CYP2B10 and 3A11, was induced by PB in CAR+/+ but not in CAR-/- mice. Although the main pathway of CCl(4)-induced acute liver injury is mediated by CYP2E1, CAR modulates its pathway via induction of CYP2B10 and 3A11 in the presence of activator or inhibitor. CONCLUSION: The nuclear receptor CAR modulates CCl(4)-induced liver injury via induction of CCl(4)-metabolizing enzymes in the presence of an activator. Our results suggest that drugs interacting with nuclear receptors such as PB might play critical roles in drug-induced liver injury or drug-drug interaction even though such drugs themselves are not hepatotoxic.
AIM: To investigate the precise roles of CAR in CCl(4)-induced acute hepatotoxicity. METHODS: To prepare an acute liver injury model, CCl(4) was intraperitoneally injected in CAR+/+ and CAR-/- mice. RESULTS: Elevation of serum alanine aminotransferase and extension of centrilobular necrosis were slightly inhibited in CAR-/- mice compared to CAR+/+ mice without PB. Administration of a CAR inducer, PB, revealed that CCl(4)-induced liver toxicity was partially inhibited in CAR-/- mice compared with CAR+/+ mice. On the other hand, androstanol, an inverse agonist ligand, inhibited hepatotoxicity in CAR+/+ but not in CAR-/- mice. Thus, CAR activation caused CCl(4) hepatotoxicity while CAR inhibition resulted in partial protection against CCl(4)-induced hepatotoxicity. There were no differences in the expression of CYP2E1, the main metabolizing enzyme for CCl(4), between CAR+/+ and CAR-/- mice. However, the expression of other CCl(4)-metabolizing enzymes, such as CYP2B10 and 3A11, was induced by PB in CAR+/+ but not in CAR-/- mice. Although the main pathway of CCl(4)-induced acute liver injury is mediated by CYP2E1, CAR modulates its pathway via induction of CYP2B10 and 3A11 in the presence of activator or inhibitor. CONCLUSION: The nuclear receptor CAR modulates CCl(4)-induced liver injury via induction of CCl(4)-metabolizing enzymes in the presence of an activator. Our results suggest that drugs interacting with nuclear receptors such as PB might play critical roles in drug-induced liver injury or drug-drug interaction even though such drugs themselves are not hepatotoxic.
Authors: Nathan J Cherrington; Dylan P Hartley; Ning Li; David R Johnson; Curtis D Klaassen Journal: J Pharmacol Exp Ther Date: 2002-01 Impact factor: 4.030
Authors: L B Moore; D J Parks; S A Jones; R K Bledsoe; T G Consler; J B Stimmel; B Goodwin; C Liddle; S G Blanchard; T M Willson; J L Collins; S A Kliewer Journal: J Biol Chem Date: 2000-05-19 Impact factor: 5.157
Authors: Yukio Yamamoto; Rick Moore; Thomas L Goldsworthy; Masahiko Negishi; Robert R Maronpot Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Wendong Huang; Jun Zhang; Steven S Chua; Mohammed Qatanani; Yunqing Han; Riccarda Granata; David D Moore Journal: Proc Natl Acad Sci U S A Date: 2003-03-18 Impact factor: 11.205
Authors: Wen Xie; Mei-Fei Yeuh; Anna Radominska-Pandya; Simrat P S Saini; Yoichi Negishi; Bobbie Sue Bottroff; Geraldine Y Cabrera; Robert H Tukey; Ronald M Evans Journal: Proc Natl Acad Sci U S A Date: 2003-03-18 Impact factor: 11.205
Authors: Simrat P S Saini; Junichiro Sonoda; Li Xu; David Toma; Hirdesh Uppal; Ying Mu; Songrong Ren; David D Moore; Ronald M Evans; Wen Xie Journal: Mol Pharmacol Date: 2004-02 Impact factor: 4.436